4 Analysts Have This to Say About Structure Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Structure Therapeutics (NASDAQ:GPCR) in the last quarter. The average 12-month price target for the company has increased by 72.22% from the previous average of $45.00 to $77.5.
October 19, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Structure Therapeutics (NASDAQ:GPCR) has received bullish ratings from analysts, with an increased 12-month price target.
The bullish ratings from analysts and the significant increase in the 12-month price target indicate a positive outlook for Structure Therapeutics. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100